Imagine this: you’re sitting on critical new data that could reshape treatment approaches. But, by the time it gets through the internal review process and the PAAB approval, that “breaking news” feels more like yesterday’s story. As pharmaceutical marketers in Canada, this is a dilemma we face all too often. We want to get fresh, relevant information to healthcare professionals (HCPs), but the lag in approvals means they’ve likely already formed an opinion or moved on.
I get it—protecting the integrity of information is crucial, and that’s why we have regulatory bodies like the PAAB ensuring accuracy and compliance. But here’s the kicker: in an era where digital tools and AI could significantly speed up this process, we’re still operating on timelines that feel more suited to the past.
Imagine if we could get that same information into the hands of HCPs within two weeks instead of months? It would be a total game changer. The technology exists. Now, the challenge is to bring the system up to speed with the needs of the present. Thoughts on how we can tackle this?
